Medeon Biodesign, Inc. (TPEX:6499)

Market Cap	8.76B +149.9%
Revenue (ttm)	381.90M +41.0%
Net Income	-739.79M
EPS	-8.03
Shares Out	92.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	686,681
Average Volume	816,380
Open	93.50
Previous Close	92.70
Day's Range	91.40 - 96.00
52-Week Range	34.75 - 154.50
Beta	0.87
RSI	51.97
Earnings Date	Feb 11, 2026

About Medeon Biodesign

Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to pr...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2012
• Employees: 39
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6499

Financial Performance

In 2024, Medeon Biodesign's revenue was 292.81 million, an increase of 49.19% compared to the previous year's 196.26 million. Losses were -805.51 million, -33.13% less than in 2023.